ABSTRACT
Accurate and complete reporting of research is required to maintain the value of the evidence base of the medical literature. High-quality reporting facilitates critical appraisal, comparison, repetition, and validation of prior studies and inclusion of studies in meta-analyses. Unfortunately, reporting is often suboptimal, and deficiencies have been documented in a wide range of study types and medical fields. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In response, researchers have developed reporting guidelines that list items that should be reported in various types of studies. The Enhancing the Quality and Transparency of Health Research (EQUATOR) network collects these guidelines and makes them available from a single website. 12 At present, the EQUATOR site lists over 350 different reporting guidelines covering a wide range of study types used in health research.
Some journals have endorsed reporting guidelines in their instructions to authors. Endorsement can range from simply mentioning reporting guidelines or stating that authors "must" follow a guideline to requiring authors to submit a completed checklist to show adherence to a guideline. A recent survey found that 106 (62%) of 168 high-impact medical journals (top five journals in 33 medical fields based on impact factor as listed by Thomson Reuters Journal Citation Reports) mentioned the Consolidated Standard of Reporting Trials (CONSORT) in their instructions to authors; 42% stated that authors must follow a guideline, and 38% required authors to submit a checklist. 13 Similar studies found that 25% of urology journals mentioned a reporting guideline, and 42% of surgery journals mentioned CONSORT in their instructions to authors. 14, 15 The extent to which pathology journals have endorsed reporting guidelines is unknown.
CONSORT is one of the most widely used reporting guidelines and has been well studied. A Cochrane review found that endorsement of CONSORT was associated with improved reporting of clinical trials. 16, 17 Although there is evidence to support endorsement of CONSORT, there is less evidence to support other guidelines. A recent systematic review that examined the impact of endorsement of other guidelines concluded that there was insufficient evidence to recommend endorsement of reporting guidelines. 18 These studies only examined the impact of endorsement and did not control for differing approaches to enforcement. The impact of endorsement may vary by guideline and on enforcement.
The objective of this study was to determine the prevalence of guideline endorsement by pathology journals and to estimate the impact of endorsement and enforcement on reporting quality. To examine the impact of endorsement, we compared the reporting quality of studies that were published in journals that explicitly mentioned reporting guidelines to the reporting quality in journals that did not. Because predictive biomarker and prognostic studies are commonly published in pathology journals, we used the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines to assess reporting quality. To examine the impact of enforcement, we compared the reporting quality of studies that cited a guideline with the reporting quality of studies that did not. It was our hypothesis that awareness or explicit use of reporting guidelines significantly increases the quality of research reporting compared with studies that do not mention any guidelines.
Materials and Methods

Assessment of Prevalence of Reporting Guideline Endorsement
We surveyed the instructions to authors of 59 leading pathology journals (as determined by Thomson Reuters ISI index) and noted any mention of any reporting guideline. The journals were surveyed November 16, 2014, and again on March 1, 2017. We noted whether the instructions explicitly mentioned reporting guidelines (suggests but does not require) or whether the journal requires that authors submit a reporting guideline checklist along with a manuscript. We also noted whether they mentioned the International Commission of Medical Journal Editors (ICMJE) guidelines.
Assessment of Impact of Guideline Endorsement
Our objective was to determine the impact of guideline endorsement on reporting quality in pathology journals. To that end, we selected two representative pathology journals from six journals that explicitly mention any reporting guidelines in the instructions to authors guidelines (American Journal of Pathology and Journal of Clinical Pathology) and four representative pathology journals that did not (American Journal of Clinical Pathology, American Journal of Surgical Pathology, Human Pathology, and Modern Pathology). We then compared the completeness of reporting in each group (scoring is described in detail below). We called this set of studies the ENDORSEMENT study group. The ENDORSEMENT study group was composed of two cohorts: endorsement positive (journals that mention reporting guidelines) and endorsement negative.
We selected studies for the ENDORSEMENT study group as follows. For each journal, we obtained all studies published in 2015 (using the journal and date filters in PubMed), and two authors (R.L.S. and J.E.C.) reviewed the titles and abstracts to obtain a pool of potentially eligible prognostic biomarker studies from each journal. Disagreements were resolved by discussion. We randomly selected 10 studies from each journal by assigning a random number to each study in the pool of eligible studies, ranking the studies by random number, and selecting the studies assigned to the top 10 random numbers. The endorsement-positive group contained 20 studies, and the endorsement-negative group contained 40 studies.
Assessment of Impact of Guideline Enforcement
Our second objective was to estimate the impact of guideline enforcement on reporting quality. For this purpose, we randomly selected 30 prognostic biomarker studies that cited the REMARK guidelines and 30 that did not. We then compared the completeness of reporting relative to the REMARK guidelines in both groups. This set of studies was called the ENFORCEMENT study group and was composed of two subgroups: citation-positive and citation-negative studies. We used citation of REMARK as an indication that study authors used the guideline. Because the citation-positive group used REMARK, we reasoned that this group could provide an estimate of reporting quality that would occur if the guideline was fully enforced. Similarly, the group that did not cite REMARK would provide an estimate of reporting quality in those that did not use the guideline.
Studies in the ENFORCEMENT group were identified as follows. We used Scopus (an electronic database similar to PubMed, published by Elsevier) to identify prognostic biomarker studies published in 2015 (using the keywords prog* and biomark*). The studies in the ENFORCEMENT study group (citation positive and citation negative) were not limited to particular journals or a particular medical discipline. We did not limit this set to studies published in pathology journals because REMARK guidelines are infrequently cited in pathology journals, and it would not have been feasible to collect a sufficient number of studies if we had limited the group to studies appearing in pathology journals. We used Scopus for this task because, unlike PubMed, Scopus is a citation database that can easily identify subsets of studies that reference a particular study. We randomly selected 30 studies from each group of potentially eligible studies. The set of selected studies was reviewed by two authors (R.L.S. and J.E.C.) for eligibility. Disagreements were resolved by discussion.
Study Evaluation
We decided to evaluate quality of reporting using a single guideline. Prognostic biomarker studies are frequently published in pathology journals, and previous research has shown deficiencies in the reporting of these types of studies. [19] [20] [21] [22] [23] Because of these deficiencies, we hypothesized that the reporting quality of prognostic biomarker studies might be sensitive to guideline endorsement or guideline use. To that end, we used the REMARK guideline and checklist. 24 The REMARK checklist contains 20 items. We developed detailed scoring criteria for each checklist item using the REMARK elaboration and explanation document. 25 The scoresheet is presented in Supplementary Table 1 (all supplemental materials can be found at American Journal of Clinical Pathology online). Some checklist items had multiple criteria. In such cases, we listed the multiple criteria as subitems to create a hierarchy or inverted tree ❚Figure 1❚. Nodes in the hierarchy form a parent-child relationship, and the lowest level nodes (ie, those without children) are study attributes. For example, item 1 (parent) had three subitems (children) designated as 1.1, 1.2, and 1.3. Item 1.1 was also composed of three criteria designated as 1.1.1, 1.1.2, and 1.1.3. The study attributes were scored as satisfactory (item score = 1) or unsatisfactory (item score = 0). The scoresheet contained a total of 71 attributes that were evaluated in each study. The score for parent nodes was obtained by averaging the scores of their direct descendants, expressed as a percentage. Thus, we were able to obtain scores for each checklist item as well as an overall score for each study (averaging overall 20 REMARK items for a particular study). The item score can be interpreted as the percentage of criteria that were satisfactorily fulfilled for a particular item. The study score can be interpreted as the average item score for a particular study. These scores assess completeness of reporting relative to the REMARK criteria. We used completeness as a measure of quality and use these terms interchangeably.
The scoring criteria were refined by conducting two pilot rounds in which two authors (R.L.S. and J.E.C.) evaluated five studies and compared results. Then, after refining the scoring criteria, all checklist items were independently scored by two of three reviewers (R.L.S., J.E.C., and J.K.M.). Each reviewer pair scored 60 studies. One reviewer (R.L.S.) assessed all articles and all items. In total, 8,520 study attributes were evaluated (71 attributes × 120 studies). The overall concordance rate was 75%, which is similar to the concordance rate reported by other researchers evaluating reporting with respect to REMARK. 26 We identified four study attributes with very low concordance (<30%). The assessment criteria for these four study attributes were refined, and these ❚Figure 1❚ Description of scoring. Scores were based on a hierarchy. The REMARK guidelines are composed of 20 items. Study scores were obtained by averaging the 20 item scores for each study. Some item scores were based on multiple criteria. In that case, each criterion was listed as a subitem, and the item score was determined by averaging the scores of the subitems. For example, the score for item 1 (0.78) was obtained by averaging the scores for items 1.1, 1.2, and 1.3. Similarly, the score for item 1.1 was obtained by averaging the scores of its subitems, 1.1.1, 1.1.2, and 1.1. 
Statistical Analysis
Statistical calculations were performed using Stata 14 (Stata LLC, College Station, TX). Univariate analysis of study scores (impact of guidelines in the ENDORSEMENT group and impact of REMARK citations in ENFORCEMENT group) was compared using the t test. The Shapiro-Wilk test was used to test for normality. Heterogeneity in item scores was assessed using Higgins I 2 statistic as implemented in the metaprop command in Stata. Univariate analysis of item scores was performed using the Wilcoxon ranksum test.
Results
Prevalence of Guideline Endorsement
We found that six (10%) of 59 pathology journals explicitly mentioned reporting guidelines in their instructions to authors (Supplementary Table 2 ). Only one journal (Journal of Clinical Pathology) required authors to submit a checklist for an appropriate guideline. Eleven journals mentioned ICJME, but most of these mentioned ICJME in the context of authorship.
Characteristics of Study Groups
The ENFORCEMENT study group contained 60 studies from 38 journals (Supplementary Table 3 ). This group contained 19 studies obtained from 12 journals that explicitly mentioned reporting guidelines in the author instructions ❚Table 1❚. Citation of REMARK was associated with mention of reporting guidelines in the ENFORCEMENT study group ( χ 1 2 = 6 2 . , P = .01). The ENDORSEMENT group (Table 1) contained 60 studies from six pathology journals, two of which mentioned reporting guidelines and four which did not (Supplementary Table 4 ). One study in the ENDORSEMENT study group cited the REMARK guideline.
Completeness of Reporting
Averaging over all studies (N = 120), we found that studies satisfactorily fulfilled about 53% of the criteria for the REMARK items (ie, in a given study, approximately 10 of 20 REMARK items were adequately addressed). The median study score was 53%, and the interquartile range was 47% to 61%. Study scores ranged from a minimum of 30% to 75%.
Reporting was more complete in studies that cited REMARK compared with studies that did not cite REMARK (P < .001), ❚Figure 2❚. The average study score (the average of the score for each REMARK item in one study) in the citation-positive group (n = 30) was 8.9% greater (95% confidence interval [CI], 5.9%-12.9%) than the average study score in the citation-negative group (n = 30).
Guideline endorsement was associated with more complete reporting as indicated by study scores. The mean difference in study scores between the endorsement-positive and endorsement-negative groups was 4.6% (95% CI, -0.6 to 9.8%; one-sided P = .04).
We found significant heterogeneity (P < .001) in item scores ❚Table 2❚ and ❚Figure 3❚. Item scores ranged from 4% (power calculations, REMARK item 9) to 92% (state marker and hypotheses, REMARK item 1). On average, studies had low item scores for treatment description (51%, REMARK item 3), a priori listing of candidate predictors (16%, item 8), description of statistical methods (32%, item 10), use of flow diagrams or REMARK profiles (5%, item 12), reporting associations between predictors (40%, item 13), reporting multivariate analysis with all candidate predictors (26%, item 17), and model validation (6%, item 18).
In the ENFORCEMENT study group, citation-positive studies generally had higher item scores (P = .02). Citing REMARK was associated with a statistically significant increase in item scores for nine of the 20 REMARK items ❚Table 3❚. Item scores in citation-positive studies were never significantly lower than item scores in citation-negative studies (Table 3) . Results in the ENDORSEMENT study group were similar ❚Table 4❚. Scores of eight REMARK items were significantly higher in the endorsement-positive cohort compared with the endorsement-negative group. One REMARK item (item 11) was lower in the endorsement-positive group. 
Discussion
Complete reporting of the results of medical studies is vital; however, it is well known that reporting is often deficient. Reporting guidelines have been developed to facilitate complete reporting, and many journals have endorsed these guidelines. We sought to determine the extent to which reporting guidelines have been adopted by pathology journals and to determine whether guideline endorsement was associated with more complete reporting. We found that only 10% of the leading pathology journals explicitly mention reporting guidelines, and only one journal required a checklist to show adherence to the guideline (Supplementary Table 2 ). We found that completeness of reporting was higher in pathology journals that explicitly mention reporting guidelines in the instruction to authors; however, the effect was relatively small. Endorsement was associated with a 4.6% increase in the percentage of completed items.
A recent systematic review and meta-analysis concluded that there was insufficient evidence to determine whether guideline endorsement improves reporting quality. 18 This review examined endorsement of five different guidelines (CONSORT extension for harms, PRISMA [Preferred Reporting Items for Systematic Reviews and Meta A recent systematic review found that 69 of 81 studies showed a benefit from endorsement of the CONSORT guideline. 16 To our knowledge, our study is the first to examine the impact of endorsement in the context of biomarker prognostic studies.
We are aware of two studies that have examined reporting quality of prognostic biomarker studies in relation to the REMARK guidelines. Jankova et al 27 evaluated studies reporting protein biomarkers for colorectal cancer. Mallet et al 22 evaluated 50 tumor marker studies covering a range of diseases. Both studies found significant deficiencies in reporting. As in our study, there was wide variation in reporting for specific items. Studies on the impact of guideline endorsement are difficult to interpret because journals may not enforce the policy. Authors may not use the guideline if it is merely suggested. For that reason, we tried to determine the impact of using a guideline. To that end, we examined the difference in reporting quality between studies that actually used a guideline and those that did not determine the potential impact of a policy that was fully enforced. We found that reporting quality was higher in articles that used a guideline (as indicated by citation of the REMARK guideline) compared with articles that did not use a guideline. We found that guideline use had a stronger effect on reporting quality than guideline endorsement. This result is consistent with the hypothesis that there is poor adherence to guideline usage in journals that endorse guidelines. Our results suggest that enforcement of guidelines should improve the quality of reporting.
Studies on the impact of guideline endorsement generally use one of two designs. One option is to compare studies selected from journals that do and do not endorse a guideline. We used this type of design in this study. The other option is to compare reporting quality before and after endorsement of a guideline within particular journals. Both types of designs suffer from interference due to variation in the degree of enforcement. We sought to limit the impact of enforcement by comparing studies from studies that claimed to use REMARK (a proxy for full enforcement) with those that did not cite REMARK. These two groups provide an estimate of the improvement that might occur if there was full enforcement. Citation of REMARK is probably a reliable indicator of guideline use; however, failure to cite REMARK is a less reliable indicator of nonuse because authors may have used REMARK without citing the guideline. The scores of the citation-negative group would be increased if the group contained authors who used the guideline, and this, in turn, would reduce the difference in scores between the citation-positive and guideline-naive groups. Our design would have been stronger if we had contacted authors in the citation-negative group and determined whether they had actually used REMARK. This is a limitation of an observational design. With few exceptions, studies on reporting guidelines have used observational designs. Randomized controlled trials are needed. 28 We are aware of one randomized controlled trial on the impact of guidelines. Cobo et al 29 randomized journal articles that had been invited for revision for a secondary review based on a relevant reporting guideline. Studies that were randomized to the intervention were referred to a statistician who added comments based on a reporting guideline. They found that the intervention (guideline-based review) was associated with an improvement in reporting.
We found that the rate of guideline endorsement in pathology journals was lower than has been reported in other fields. Use of guidelines by authors or endorsement by editors depends on many factors, and editors may be uncertain whether the benefits are worth the cost. 30 We found that the benefits were modest even in the group that cited REMARK. Enforcement of guidelines may place a burden on authors and reviewers. On the other hand, some have argued that adherence to guidelines may reduce costs by reducing review time, requests for revisions, and the publication of false leads. 31 It is unclear whether the low rate of guideline endorsement is due to cost-benefit considerations that are unique to pathology or other factors. We note that College of American Pathologists checklists are also a form of guideline. Like reporting guidelines, they impose some costs, but they have been widely adopted because they improve the quality of reporting.
Our study has several limitations. We only examined the impact of endorsement on the REMARK guideline in pathology journals. It is unclear whether our results can be generalized. Our study would have been stronger if we had examined several guidelines; however, we found that assessment of 120 studies was a time-consuming process. Performing evaluations for multiple guidelines would not have been practically feasible. The subgroups in our ENDORSEMENT group might have been biased by selection of journals. It would have been better to randomly select journals if a set of similar journals were available. Unfortunately, this was not the case. The set of leading journals contains a wide range of journals, many of which are highly specialized. We attempted to pick a set of comparable and representative journals that frequently publish biomarker studies and are not highly specialized.
We believe our study also has several strengths. We evaluated a large number of studies (N = 120) relative to similar evaluation studies. For example, other REMARK studies evaluated 50 and 80 articles. 22, 27 We followed a systematic process of article selection and validation of our scoring method. Finally, our study design addressed a key limitation of endorsement studies. By comparing studies that cite and do not cite REMARK, we attempted to estimate the benefits that might be obtained with a high level of enforcement.
In conclusion, our results show that there is significant room for improvement in reporting quality of prognostic biomarker studies. Very few pathology journals have endorsed reporting guidelines, and only one requires checklists. Our results suggest that endorsement may help to improve reporting quality and that reporting quality could be further improved by enforcement.
Complete and transparent reporting will improve the value of the evidence base by facilitating validation of published reports, incorporation of data into meta-analyses, and the practice of evidence-based medicine.
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